Document is current

Article History

Received: 20 April 2022

Accepted: 23 January 2023

First Online: 30 January 2023

Declarations

:

: This study was performed following the Helsinki Declaration. The study was conducted according to national regulations, as described by Royal Decree 1090/2015. According to the aforementioned legislation, due to the nature of the study, approval by an ethics committee was not required.

: Not aplicable.

: MC has received speaking fees from Boehringer Ingelheim, CSL Behring, AstraZeneca, GlaxoSmithKline, Griffols, Menarini, and Novartis and consulting fees from GlaxoSmith­Kline, Gebro Pharma and Novartis. JLLC has received honoraria for lecturing, scientific advice, participation in clinical studies or writing for publications for AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, CSL Behring, Ferrer, Gebro, GlaxoSmithKline, Grifols, Menarini, Megalabs, Novartis and Rovi. MM has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Zambon, CSL Behring, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Inhibrx, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, Spin Therapeutics, ONO Pharma, pH Pharma, Palobiofarma SL, Takeda, Novartis, Sanofi and Grifols and research grants from Grifols. FJMDLR has received speaker fees and/or consulting fees and/or support to attend Congresses from AstraZeneca, Boehringer-Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Grifols, Menarini, Novartis, Sanofi and Teva. JMHP has received speaker fees from GRIFOLS, CSL Behring, GSK, Astra-Zeneca, Menarini Laboratories, Boehringer Ingelheim, FAES, Esteve Laboratories, Ferrer Laboratories, Mundipharma, Rovi Laboratories, Roche, Novartis, Pfizer, Acthelion-Jansen, Chiesi and Bial Laboratories for the conducting courses, talks, consultancies and other activities related to my professional activity. CMM has received speaking and consulting fees from CSL Behring and Grifols. JBMR has received speaker fees and/or consulting fees and/or support to attend Congresses from CSL Behring, NovoNordisk, Grifols, Pfizer, Biotest and Takeda. FCM has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Glaxo Smith Klein, Grifols and Novartis, consulting fees from AstraZeneca, Glaxo Smith Kline, CSL Behring, Sanofi and Grifols. JLRH has received speaker fees from CSL Behring and Grifols, and research grants from Grifols. ET has received consulting fees from CSL Behring. JMMS has received honoraria for conducting courses and consultancy from CSL Behring. CMR has received honoraria during the last 3 years for lecturing, scientific advice and participation in clinical studies from Glaxo SmithKline, Astra Zeneca, TEVA, Sanophi, CSL Behring, Mundipharma, Chiesi, Orion and Novartis. FJCG has received honoraria during the last 3 years for lecturing and scientific advice from GlaxoSmithKline, Chiesi, Boehringer Ingelheim, Mundipharma, Pfizer, Novartis, Esteve, Teva Pharmaceutical, Ferrer, Rovi, Roche, Astra Zeneca, Bial, Actelion, Alter, CSL Behring, Faes Farma, Alter, Grifols, Sanofi Genzyme y Gebro Pharma. MTD has received speaking and consulting fees from CSL Behring and Grifols.